Xortx Therapeutics

What Xortx Therapeutics does

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company founded in 2012 and headquartered in Calgary, Canada, listed on NASDAQ under ticker XRTX (having voluntarily delisted from the TSX Venture Exchange in June 2026). The company is pre-revenue with a headcount of 1-10 employees and an accumulated deficit of approximately $23.8M as of December 31, 2025. XORTX's business is the development of proprietary small-molecule therapies based on xanthine oxidase inhibition, anchored by its XORLOTM oxypurinol formulation technology licensed from the University of Florida Research Foundation.

The pipeline is diversified across four renal and metabolic indications: XRx-026 (pre-NDA in gout for allopurinol-intolerant patients), XRx-008 (ADPKD, FDA Orphan Drug Designation), XRx-101 (COVID-19-associated kidney injury), XRx-225 (Type 2 diabetic nephropathy, pre-clinical), and the recently acquired VB4-P5 anti-fibrotic program (pre-IND). XRx-026 is advancing via the 505(b)(2) NDA pathway following a Type B meeting with the FDA in June 2026, making it the lead asset closest to potential commercialization.

The business model is a classic clinical-stage biotech: XORTX funds operations through repeated small public equity offerings — approximately $18.6M raised cumulatively since 2021, including a $5M public offering in May 2026 — with annual net losses of roughly $2.5M-$3.3M and no current licensing or product revenue. Future monetization is expected through direct commercialization or out-licensing of approved therapies to specialty or rare-disease partners, targeting addressable populations in gout (~3-5% of allopurinol-intolerant patients), ADPKD, and broader chronic kidney disease with fibrosis.

Name

Xortx Therapeutics

Legal name

XORTX Therapeutics Inc.

Website

https://xortx.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

XORTX Therapeutics is a late-stage clinical pharmaceutical company developing proprietary oxypurinol-based therapies (XORLOTM) for gout patients intolerant to allopurinol and for progressive kidney diseases including ADPKD, diabetic nephropathy, and COVID-19-related kidney injury.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Nephrology and Gout)

NAICS

Medical and Diagnostic Laboratories (6215), Kidney Dialysis Centers (621492)

SIC

Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

Keywords

• Clinical pharmaceutical development
• Xanthine oxidase inhibition
• Uric acid lowering therapy
• Kidney disease therapeutics
• Gout treatment drugs

Headquarters

HQ city

Calgary

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue company. Will generate revenue through commercialization of prescription pharmaceutical products targeting gout and kidney diseases upon FDA approval. The lead product XRx-026 targets a US$700 million per year market opportunity.
2. Licensing Royalties: Company has licensing agreement with University of Florida Research Foundation Inc. for intellectual property related to xanthine oxidase inhibition technology.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

XORTX Therapeutics is a late-stage clinical pharmaceutical company developing proprietary oxypurinol-based (XORLOTM) uric acid-lowering therapies for gout and progressive kidney disease. The lead program XRx-026 is at pre-NDA filing for gout patients intolerant to allopurinol (3-5% of patients), with additional programs targeting ADPKD (XRx-008, Orphan Drug Designation), acute kidney injury from respiratory viruses (XRx-101), and Type 2 Diabetic Nephropathy (XRx-225). The company acquired the VB4-P5 kidney anti-fibrotic program from Vectus Biosystems in April 2026.

Product overview

XORTX Therapeutics is a late-stage clinical pharmaceutical company developing a pipeline of uric acid-lowering agents targeting aberrant purine metabolism. The company has four core programs: XRx-026 (pre-NDA stage for gout), XRx-008 (Phase 3 planned for ADPKD, Orphan Drug Designation), XRx-101 (Phase 3 planned for acute kidney injury from respiratory viruses), and XRx-225 (pre-clinical for Type 2 Diabetic Nephropathy). The company also acquired VB4-P5 (pre-IND kidney anti-fibrotic). All programs utilize the proprietary oxypurinol formulation XORLOTM to inhibit xanthine oxidase and reduce uric acid production. One program is at pre-NDA filing stage, two are in clinical development, and one is at early pre-clinical stage.

Differentiator

Problem solved

Functional benefit

Products and services

• XRx-026

Quantifiable outcome

• US$700 million per year target market opportunity for XRx-026 in gout patients intolerant to allopurinol
• +2 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Vectus Biosystems LimitedcoreStrategic or Co-development Partner · 17 October 2025Xortx acquired the Renal Anti-Fibrotic Therapeutic Program including novel chemical entity VB4-P5, associated intellectual property, regulatory documentation, and manufacturing data. Deal valued at US$3.0 million paid through 154,544 common shares and 692,150 pre-funded warrants. The program targets both rare and prevalent forms of chronic kidney disease characterized by fibrosis.
• University of Florida Research Foundation Inc. (UFRF)coreTechnology or Integration · 9 October 2012Licensing agreement for intellectual property related to xanthine oxidase inhibition technology and related compounds. The technology was developed by Dr. Richard Johnson and Dr. Takahiko Nakagawa. License agreement covers technology for treating conditions modulated by aberrant purine metabolism.

Scale indicators11 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• ProKidney: Clinical-stage cell therapy company (rilparencel) targeting chronic kidney disease and diabetic kidney disease. Comparable as a small-cap, late-clinical nephrology-focused biotech pursuing CKD indications.
• Selecta Biosciences (now Cartesian Therapeutics): Was a clinical-stage immunology company developing SEL-212 (pegadricase + rapamycin) for refractory gout. Comparable as a small clinical-stage biotech directly addressing the same allopurinol/febuxostat-intolerant gout segment that XRx-026 targets.
• Travere Therapeutics: Small clinical-stage rare disease company with approved kidney drug Filspari (sparsentan) for IgA nephropathy and FSGS. Highly comparable given similar size, kidney-disease focus, and specialty pharma commercial model.
• Chinook Therapeutics (acquired by Novartis): Clinical-stage nephrology company developing treatments for ADPKD and IgA nephropathy (atrasentan, zigakibart) prior to its 2023 acquisition by Novartis. Directly comparable to XORTX's ADPKD program XRx-008 in target indication and stage.

Broad incumbents

• Otsuka Pharmaceutical: Large Japanese pharma with Jynarque (tolvaptan) — the only FDA-approved therapy to slow ADPKD progression. Directly competes with XORTX's XRx-008 in the ADPKD indication, though Otsuka operates across many other therapeutic areas.
• Amgen (Horizon Therapeutics): Amgen acquired Horizon Therapeutics in 2023, gaining Krystexxa (pegloticase) for refractory/chronic gout. Directly relevant to XORTX's XRx-026 target patient population (treatment-refractory gout), though Amgen is a broad large-cap incumbent.

Emerging players

• Galapagos NV: European clinical-stage biotech that pivoted toward CAR-T and renal disease programs after restructuring. Comparable as a smaller biotech strategically reorienting toward nephrology indications similar to XORTX's pipeline.
• Swedish Orphan Biovitrum (Sobi): Specialty rare-disease biotech with presence in gout and inflammatory diseases (Kineret, caspofungin). Comparable as a specialty pharma pursuing orphan and rheumatology indications overlapping with XORTX's nephrology/gout focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/xortxcom

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds9 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xortx Therapeutics